1. Jusvinza treatment resolution in confirmed COVID-19 patients. Santiago de Cuba, 2021
- Author
-
Sandra Caridad Laurencio Vallina, Martha María Arias Carbonell, Leonardo Ramos Hechavarría, Dayami Lescay Balanquet, and Roger Pina Núñez
- Subjects
infecciones por coronavirus ,factores inmunitarios ,morbilidad ,mortalidad ,resultado del tratamiento ,Medicine (General) ,R5-920 ,Public aspects of medicine ,RA1-1270 - Abstract
Foundation: SARS-CoV-2 infection is the most important emerging disease of this century. In this context, the Cuban Biotechnology and Pharmaceutical Industries Group (BioCubaFarma) created therapeutic alternatives to combat COVID-19, including the use of Jusvinza, which is part of the protocol used in the country. Objective: to determine the Jusvinza therapeutic resolution in confirmed COVID-19 patients. Methods: a descriptive study carried out from January to September 2021, at the Dr. Joaquín Castillo Duany Military Hospital, in Santiago de Cuba. The universe consisted of 166 confirmed COVID-19 cases, to whom Jusvinza was administered. Some clinical variables (clinical status, associated non-communicable diseases, clinical progression), epidemiological (age, sex) and pharmacological (resolving, duration in days) were analyzed. A data extraction form was used, which was taken from the medical records. Results: morbidity and mortality from COVID-19 was higher in males, related to comorbidities and age over 60 years; The female sex was the one with the greatest response to treatment with Jusvinza (71.7%), which increased its percentage in the absence of associated chronic non-communicable diseases (81.4%). High-risk patients had the lowest mortality (15.8%). Conclusions: resolution in confirmed COVID-19 patients treated with Jusvinza was higher in high-risk cases than in severe and critical cases.
- Published
- 2024